I am still here .. I bought a large position of Gbim when it was in mid 70 cente
We now own 1/3 of old Biod pipeline ..2/3 goes to ALBO old shareholders .. Also our cash is gong to be used to fund ALBO dev .. They should have sold pipeline instead of RM
But am hoping ALBO pipeline is good ..
deals in the range of $35 to $50M with promising pipeline/partnered assets and very low cash burn
I am long GBIM and am wondering if Adxs is planning to acquire them
Sellers are giving zero possibility that phase 3 data for 12 to 13 sites were switched placebo with drug
I don't see this as a small possibility .. How could drug produce positive effects as compared to placebo for ALL 100 patients in phase 2b for all 11 questions and do same for 38 sites and then 12 sites do the exact opposite ??
If data were switched for those 11 sites, they have met p3 and thsi should go to $20
Gi-6100 program .. If celg moves to phase 1, Gbim will Likley receive $5M or 88 cents a share
Why are all potential catalysts ?
1-,6100 to phase 1
2- 4774 to phase 2b
3- MTC to next phase
4- Sale of gi-4000
6-Chordoma next phase ?
More importantly . P was .002 in those 13 sites .. That is highly stat significant .. I.e placebo did much much better
It is small errors that are hard to find .. But not very very big ones like this one
They are telling you that treated in those 13 sites were quite a bit worse off that placebo .. So , either the drugs were switched . Then can confirm it by Looking at PK .. Or drug not only does not work but it is much worse than placebo .. A drug that has been around for a while for this indication
.002 means if you repeat test 500 times .. 499 times you get same answer
.006 means if you repeat test 166 times, 165 times you get same answer
The odds results are correct is about 1 in 82,000
Lol .. That was funny
I would cover now .. What are odds that 2/3 of sites shows results one way with .006 p and 1/3 show the other way with .002 p .. And no mistake happened
Once news hits that there was a mistake it will go up .. Not sure by how much
They were in default so they had no choice but to do a secondary
1-,no error and their tech does not work. ..
So shares are worthless
2- an error occurred , but FDA wants a new p3 .. In this car company will be sold maybe around $2 tic$4 a share
3- an error occurred like the 13 centers and FDA does not require a new p3 .. In this case shares will go to $15